Non-small cell lung cancer biorepository clinical trials in Oklahoma City, OK

Feeling difficulty in breathing?

Enroll in our non-small cell lung cancer biorepository research study today.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and it typically grows and spreads more slowly than other forms of lung cancer. There are treatment options available, however, the need to find a better and more effective cure option still remains.

Hightower is currently conducting non-interventional non-small cell lung cancer biorepository clinical trials in Oklahoma City, OK, for patients suffering with this condition. The study collects clinical and molecular health information, including longitudinal blood samples, alongside standard care and disease monitoring. The goal is to track the molecular changes in lung cancer during treatment and evaluate the use of ctDNA dynamics to predict risk of recurrence and treatment outcomes.

Participating in the clinical trial is entirely free and completely your choice.

*If you’re interested, simply fill out the form. Then, someone from our research team will get in touch to check if you are eligible for the study.*

About Non-Small Cell Lung Cancer Biorepository Clinical Trials

Hightower is conducting NSCLC Biorepository study in Oklahoma City, OK, through a longitudinal blood collection method for screening this biorepository condition.

The NSCLC Study is a non-interventional clinical study aimed at gathering clinical and molecular health data from patients with non-small cell lung cancer (NSCLC). Participants will have their blood collected over time, alongside their regular treatment and disease monitoring.

The study aims to track how lung cancer progresses during standard care and assess how ctDNA levels can help predict the risk of recurrence and treatment outcomes.

*All study procedures, including the treatment and the investigational drug, are free of any charges, and you don’t need insurance to participate.*

*The study doctor will walk you through every step of the clinical trial and answer any questions you have about the treatment before you decide whether to join.*

Biorepository Clinical Study: What to Expect?

Once you agree to participate in our study, you’ll be asked to sign an Informed Consent Form that outlines all the study details. Our research team will guide you through the process and clarify your role in the trial. We encourage you to ask any questions you may have before deciding whether to join or withdraw from the study.

After you sign the consent form for biorepository-related clinical trials, we will collect your samples on each visit.

All care related to the study is free. Moreover, appointed physicians will perform thorough physical exams and screening throughout the clinical trial

Once you decide to enroll in the study, you will be provided with an Informed Consent Form.

Once you go through it and agree with the study details, you will be asked to sign the form. Our research team will assist you through every step of the detail and summarize your role in the trial. We encourage you to ask any questions before deciding to participate or withdraw from the process.

Once the study starts, there will be two groups or cohorts formed. One will include early-stage cancer patients while the second group will include participants with advanced stage cancer. Both groups will undergo blood sampling for biomarker profiling time after time.

Cohort 1 will consist of patients in the early stages of cancer (Stages I to IIIB) who can receive treatment aimed at curing the disease. It may involve surgery and possibly additional therapy before or after the surgery.

Cohort 2 will include patients with stage IV cancer who are receiving their first treatment with immunotherapy, either on their own or combined with chemotherapy.

All care related to the study is free. Moreover, appointed physicians will perform thorough physical exams or screening throughout the clinical trial.